Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL8010851 | 0.95 | PRCP (0.32) | NOS2NOS3NOS1PRCPDPP7 | |
| Proline SCHEMBL27957063 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| Proline SCHEMBL140699 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| Proline SCHEMBL285830 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| Proline SCHEMBL3519300 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| Proline SCHEMBL140697 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| Proline SCHEMBL2588291 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| Proline SCHEMBL285829 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| Leucine SCHEMBL7856418 | 0.90 | SLC7A5 (0.49) | NOS2NOS3NOS1PRCPDPP7 | |
| Proline SCHEMBL499449 | 0.89 | NOS2 (0.42) | NOS2NOS3NOS1PRCPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156979-A1 | ANTI-INFLAMMATORY SIGLEC PROTEINS AND METHODS OF MAKING AND USING SAME | PALLEON PHARMACEUTICALS INC (US) | 2024-05-16 | — | — | US | claimed |
| EP-3146977-B1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-08 | — | — | EP | claimed |
| WO-2024064713-A1 | NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND CD228 | SEAGEN INC. (US) | 2024-03-28 | — | — | WO | claimed |
| WO-2024055076-A1 | METHODS OF DETECTING IMMUNE CELLS | BIOSCEPTRE (AUST) PTY LTD (AU) | 2024-03-21 | — | — | WO | claimed |
| US-20240066137-A1 | NOVEL PROTEIN CONJUGATE, AND USE THEREOF FOR PREVENTING OR TREATING NONALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | ONEGENE BIOTECHNOLOGY INC. (KR) | 2024-02-29 | — | — | US | claimed |
| EP-4323378-A2 | ANTI-INFLAMMATORY SIGLEC PROTEINS AND METHODS OF MAKING AND USING SAME | Palleon Pharmaceuticals Inc. (US) | 2024-02-21 | — | — | EP | claimed |
| US-11890327-B2 | Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder | CSL Behring Lengnau AG (CH) | 2024-02-06 | — | — | US | claimed |
| CN-117500818-A | Anti-inflammatory Siglec proteins and methods of making and using the same | 帕利昂制药有限公司 | 2024-02-02 | — | — | CN | claimed |
| US-20230398187-A1 | Regenerative Polypeptides and Uses Thereof | JUVENA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | US | claimed |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-12-07 | — | — | US | claimed |
| US-9045526-B2 | Compound and method for modulating opioid receptor activity | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-06-02 | — | — | US | claimed |
| US-9018167-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140154272-A1 | COMPOUND AND METHOD FOR MODULATING OPIOID RECEPTOR ACTIVITY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-05 | — | — | US | claimed |
| EP-2723761-A1 | COMPOUND AND METHOD FOR MODULATING OPIOID RECEPTOR ACTIVITY | The Regents of The University of Michigan (US) | 2014-04-30 | — | — | EP | claimed |
| US-20130259863-A1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | US | claimed |
| US-8450275-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL INC. (US) | 2013-05-28 | — | — | US | claimed |
| CN-103025345-A | TFPI inhibitors and methods of use | BAXTER INT | 2013-04-03 | — | — | CN | claimed |
| EP-2547355-A2 | TFPI INHIBITORS AND METHODS OF USE | Baxter International Inc. (US) | 2013-01-23 | — | — | EP | claimed |
| WO-2012178063-A1 | COMPOUND AND METHOD FOR MODULATING OPIOID RECEPTOR ACTIVITY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-12-27 | — | — | WO | claimed |
| WO-2011115712-A2 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC (US) | 2011-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066137-A1 | NOVEL PROTEIN CONJUGATE, AND USE THEREOF FOR PREVENTING OR TREATING NONALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | FABP1, SUMO3, SUMO2 | NOS2 2395/4885NOS3 1889/4885NOS1 2226/4885 |
| US-20140154272-A1 | COMPOUND AND METHOD FOR MODULATING OPIOID RECEPTOR ACTIVITY | OPRL1, OPRD1, OPRK1 | NOS2 996/4885NOS3 461/4885NOS1 1231/4885 |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | FAP, FIBP, FUCA2 | NOS2 4451/4885NOS3 4793/4885NOS1 4534/4885 |
| US-20130259863-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | NOS2 3014/4885NOS3 2528/4885NOS1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.